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SUMMARY

Competition for nutrients like glucose can metabolically restrict T cells and contribute to their hyporesponsiveness during cancer. Metabolic adaptation
to the surrounding microenvironment is therefore
key for maintaining appropriate cell function. For
instance, cancer cells use acetate as a substrate
alternative to glucose to fuel metabolism and growth.
Here, we show that acetate rescues effector function
in glucose-restricted CD8+ T cells. Mechanistically,
acetate promotes histone acetylation and chromatin
accessibility and enhances IFN-g gene transcription
and cytokine production in an acetyl-CoA synthetase
(ACSS)-dependent manner. Ex vivo acetate treatment increases IFN-g production by exhausted
T cells, whereas reducing ACSS expression in
T cells impairs IFN-g production by tumor-infiltrating
lymphocytes and tumor clearance. Thus, hyporesponsive T cells can be epigenetically remodeled
and reactivated by acetate, suggesting that pathways regulating the use of substrates alternative to
glucose could be therapeutically targeted to promote
T cell function during cancer.
INTRODUCTION
Metabolic fitness is important for proper T cell function. Upon
activation, T cells require increased glucose uptake to meet
the energy and biosynthesis demands required for T cell activation, clonal expansion, and effector function (Pearce and Pearce,
2013; Pearce et al., 2013). Many observations collectively support the importance of glucose for T cell responses. Culturing
T cells in limited glucose inhibits the proliferation, survival, and

expression of effector molecules, including interferon-g (IFN-g)
(Cham et al., 2008; Cham and Gajewski, 2005; MacIver et al.,
2013). Similarly, surface expression of the glucose transporter
Glut-1 is critical during activation to sustain T cell effector function (Jacobs et al., 2008). Glycolysis promotes IFN-g expression
both through epigenetic and post-transcriptional mechanisms
(Chang et al., 2013; Peng et al., 2016), whereas glycolysis inhibition leads to increased expression of immune-regulatory receptors, such as programmed cell death protein-1 (PD-1), which can
drive T cell exhaustion (Bengsch et al., 2016; Patsoukis et al.,
2015).
Further in vivo models support the importance of glucose
availability to sustain T cell function. T cells isolated from fasting
animals exhibit long-lasting metabolic and functional defects
marked by decreased glucose uptake (Saucillo et al., 2014).
Also, T cells in the tumor microenvironment must compete with
tumor cells for available glucose, which limits T cell activity and
favors tumor progression (Chang et al., 2015; Ho et al., 2015).
Effector T cells and tumor cells share many metabolic features,
such as engaging Warburg metabolism (aerobic glycolysis) or
exhibiting increased dependence on glutamine to support
biosynthesis needs. Tumor cells and immune cells also compete
for other nutrients, such as the amino acids tryptophan and arginine (Renner et al., 2017).
It is well recognized that the short-chain fatty acid acetate is an
important alternative carbon source for cancer cells to support
survival and proliferation under low-glucose conditions (Bulusu
et al., 2017; Comerford et al., 2014; Lyssiotis and Cantley,
2014; Schug et al., 2015). Acetate also has a major effect on immune cell function. For example, a systemic increase in acetate
induced by infection is required for optimal memory CD8+ T cell
function via a mechanism involving increased GAPDH acetylation and enhanced glycolysis (Balmer et al., 2016). Furthermore,
addition of acetate in vitro has been shown to enhance IFN-g
gene transcription (Peng et al., 2016). Further stressing the role
of acetate in enhancing the immune response, synthesis of
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Figure 1. Supplemental Acetate Promotes
IFN-g Production in T Cells under Chronic
Glucose Restriction
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acetate from ethanol is critical for enhancing the inflammatory
response in macrophages through increased histone acetylation
at promoter regions of pro-inflammatory genes in acute alcoholic
hepatitis (Kendrick et al., 2010). Given the potential competition
between tumor cells and effector T cells to access glucose, we
set out to explore whether acetate could correct cytokine
production in glucose-restricted T cells and, ultimately, T cells
in the tumor microenvironment.
RESULTS
Acetate Restores IFN-g Production in T Cells under
Chronic Glucose Restriction
To understand how T cells metabolically adapt to nutrientrestrictive environments, we established an in vitro model in
which naive OT-I T cells were activated with ovalbumin (OVA)
peptide in medium containing 25 mM glucose and then cultured
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(A) In vitro culture system. Splenic naive OT-I CD8+
T cells were activated with SIINFEKL peptide and
IL-2 and maintained for 3 days in medium containing 25 mM glucose. Then T cells were transferred to medium containing 1 mM glucose for an
additional 1 or 5 days. 1 day prior to analysis,
T cells were treated with or without 5 mM acetate.
Analysis was performed on days 5 and 9.
(B) FACS analysis of IFN-g production by T cells
cultured as described in (A). Numbers show percentages of IFN-g+ cells. VPA, valproic acid. FACS
plots are representative of n = 4 independent
experiments.
(C) Quantification of IFN-g production as mean
fluorescent intensity (MFI) of the CD8+ population.
Values were normalized to the 1 mM condition.
Mean ± SEM, Student’s t test, n = 4 independent
experiments.
(D) Real-time PCR of Ifng mRNA in cells cultured
as described in (A). Values were normalized to
Hprt. Mean ± SEM, Student’s t test, n = 3 independent experiments.
(E) ELISA quantification of IFN-g production by
T cells cultured as described in (A) upon restimulation of 106 cells with PMA-ionomycin for 4 h.
Mean ± SEM, Student’s t test, n = 3 independent
experiments.
(F) Number of live cells harvested after 24 h of
culture under the indicated conditions after
seeding 106 cells/mL. Mean ± SEM, n = 2 independent experiments.
(G) Analysis of cell proliferation using CellTrace
Violet dye. The graph shows the fraction of cells
diluting the dye over 24 h of culture under the
indicated conditions. Mean ± SEM, n = 2 independent experiments.
(H) Quantification of lactate production as a measure of aerobic glycolysis in the medium of cells
cultured for 24 h under the indicated conditions.
Mean ± SEM, n = 2 independent experiments.

in medium containing 1 mM glucose for 1 or 5 days, followed by
overnight culture supplemented with or without 5 mM acetate
(Figure 1A). To examine how acetate affects T cell responsiveness in low glucose, we measured intracellular IFN-g after phorbol 12-myristate 13-acetate (PMA)-ionomycin restimulation. As
expected, T cells cultured in 1 mM glucose produced significantly less IFN-g compared with T cells cultured in 25 mM
glucose (Figures S1A and S1B). However, IFN-g expression
was markedly increased in cells that had been supplemented
with 5 mM acetate compared with those in 1 mM glucose alone
(Figures 1B and 1C). These effects were accompanied by an
associated increase in Ifng mRNA after acetate treatment (Figure 1D). Acetate also significantly boosted IFN-g secretion by
cells from the day 9 time point, suggesting that the effect of acetate intensifies over prolonged glucose restriction (Figure 1E).
Importantly, supplemental acetate did not affect cell survival
(Figure 1F), proliferation (Figure 1G), or lactate secretion

(Figure 1H), which was instead decreased in cells cultured
in 1 mM glucose compared with cells cultured in 25 mM glucose
(Figure S1C). These data indicate that, although acetate
substituted for glucose in terms of restoring cytokine production,
it did not substitute for glucose in other metabolic processes in
the cell. Furthermore, supplemental acetate had little effect on
CD8+ T cell activation marker expression (Figure S1D), cell size
(Figure S1E), and granzyme B expression (Figure S1F).
Based on earlier work (Kendrick et al., 2010), we reasoned that
the increased IFN-g mRNA (Figure 1D) could reflect the ability of
acetate to substitute for glucose-derived citrate in the production of acetyl-CoA, which serves as an acetyl donor for histone
acetylation and, therefore, supports gene transcription. Consistent with this idea, we observed enhanced IFN-g protein and Ifng
mRNA expression in T cells exposed to valproic acid (VPA), a
histone deacetylase inhibitor that augments global histone
acetylation (Göttlicher et al., 2001) (Figures 1B–1D). These results illustrate that increased histone acetylation correlates
with enhanced T cell effector function, even in T cells exposed
to low-glucose conditions (Agarwal et al., 2009; Araki et al.,
2008).
Acetate Is Incorporated into Histones and Enhances
Histone Acetylation in Glucose-Restricted T Cells
To determine whether acetate enhances IFN-g production in
glucose-deprived T cells by promoting histone acetylation and
supporting gene transcription, we first asked whether glucoserestricted T cells are able to competently acquire and utilize
exogenous acetate. Acetate enters cells through monocarboxylate transporters (MCTs) or aquaporins (Halestrap and Wilson,
2012; Kirat and Kato, 2006; Kirat et al., 2006; Rae et al., 2012)
and, when in the cell, can be converted to acetyl-coenzyme A
(CoA) (Watkins et al., 2007) by one of three acetyl-CoA synthetase enzymes (ACSS1–ACSS3). Acetyl-CoA is essential for
many biological processes, including protein acetylation and
lipogenesis. Because MCT-1 and MCT-4 have been reported
to mediate significant transport of acetate in many tissues (Merezhinskaya et al., 2004), we questioned whether glucoserestricted T cells were competent in importing exogenous
acetate. We observed that MCT-1 and MCT-4 proteins were
expressed on T cells over a range of glucose concentrations
(Figures S2A and S2B). Moreover, their expression was stable
throughout the duration of the culture, supporting the notion
that T cells could acquire acetate when available in the extracellular environment. We also found that ACSS2, the isoform that
plays the dominant role in acetate utilization in mammalian cells
(Comerford et al., 2014), was expressed in T cells and was unaffected by glucose concentration (Figure S2A).
To assess whether T cells acquired exogenous acetate, we
exposed activated T cells to radioactive [1,2-14C] acetate and
measured the incorporation of 14C into histones and lipids. 14C
was enriched in both histones (Figure 2A) and lipids (Figure S2C).
We next assessed global histone acetylation in glucose-restricted
T cells by western blotting. We found that acetylation of the histone proteins H3 and H4 was increased by supplemental acetate
(Figure 2B). We also observed that T cells under prolonged
glucose restriction (day 9) had lower H3K9-14 and H3K27 acetylation compared with cells under acute glucose restriction (day 5),

and these acetylation marks were restored by addition of acetate
(Figures 2C and S2D). Of note, VPA treatment increased histone
acetylation at all time points (Figures 2B and 2C).
We further assessed the effects of supplemental acetate on
histone acetylation by performing genome-wide ChIP sequencing
analysis of acetylation of H3K27 in T cells cultured in 1 mM
glucose with or without supplemental acetate. We found that acetate supplementation modestly increased H3K27 acetylation in
an area of 2 kbp around the transcription start sites (TSSs) of
genes in clusters 1, 2, and 3, where clusters are defined by their
similarity in H3K27 acetylation profile (Figures 2D and 2E); no
substantial H3K27 acetylation was detected around the TSSs
of genes in cluster 4. This analysis also revealed that there
was no marked difference in the pattern of H3K27 acetylation
around TSSs but, rather, that acetate supplementation globally
enriches the overall level of acetylation (Figure 2E). These findings
are in keeping with our hypothesis that glucose-restricted T cells
are able to acquire and utilize acetate to promote histone
acetylation.
Acetate Promotes Chromatin Accessibility in GlucoseRestricted T Cells
The increased histone acetylation, a process known to correlate
with transcriptional activation (Allfrey et al., 1964; Verdin and Ott,
2015), evident in glucose-restricted T cells after supplemental
acetate prompted us to perform ATAC-seq analysis. We expected these data to reveal whether the enhanced histone acetylation evident after acetate treatment was linked to changes in
chromatin accessibility. We compared the chromatin profiles of
T cells cultured in 1 mM glucose with or without supplemental
acetate from different time points (day 5 and 9). We found that
day 5-activated T cells cultured in 1 mM glucose with acetate
had increased chromatin accessibility at 41 regions (Figure 3A)
compared with cells cultured in 1 mM glucose alone. Cells that
were cultured for an additional 4 days in 1 mM glucose (day 9)
and then treated with acetate showed increased accessibility
at 255 regions (Figure 3B) compared with cells cultured in
1 mM glucose alone. Together, our data show that acetate promotes histone acetylation and chromatin accessibility in T cells
that are under glucose-limiting conditions and that this effect
of acetate intensifies the longer the cells are deprived of glucose.
We also performed a pathway analysis of the 263 genes
marked by peaks after acetate treatment on day 9 and found
that the majority of significant gene ontology terms were related
to signaling pathways (Tables S1A and S1B). Of note, one of
these genes was Bhlhe40, which is a transcription factor that is
critical for T cell function (Lin et al., 2014) and for maintaining
active histone marks at the loci of CD8+ T cell effector molecules
(Li et al., 2018, J. Immunol., abstract). Overall, the data suggest
that, in the face of glucose restriction, supplemental acetate
facilitates chromatin accessibility at genes that promote CD8+
T cell effector function.
Acetate Augments Expression of a Cohort of
Restimulation-Associated Genes in Glucose-Restricted
T Cells
To assess whether acetate treatment increases effector gene
expression in T cells experiencing glucose restriction, we
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performed RNA sequencing (RNA-seq) analysis on T cells after
PMA-ionomycin restimulation. Principal-component analysis
revealed that the most significant changes in gene expression
correlated to the length of time in culture, whereas, by comparison, acetate supplementation had a limited effect on the transcriptional profiles (Figure 3C). Focusing on analysis of different
time points, we found that acetate supplementation substantially
affected the transcriptional landscape of cells cultured in 1 mM
glucose, with 1,109 differentially expressed genes (DEGs) on
day 5 and 461 DEGs on day 9, between the conditions (Figure 3D). A cohort of 151 DEGs was commonly regulated by
acetate at both time points (Figure 3D). To assess whether
acetate had any transcriptional effect on effector T cell function,
we performed a gene ontology analysis of the DEGs identified
in Figure 3D and concentrated on the top 5 enriched pathways
in each group (Figure 3E). We identified a cohort of restimula-
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Figure 2. Acetate Is Incorporated into Histones and Enhances Histone Acetylation in
Glucose-Restricted T Cells
(A) Quantification of [1,2-14C] acetate-derived 14C
incorporation in histones extracted from T cells
cultured in 10 mM glucose medium. Mean ± SEM;
n = 2 independent experiments.
(B) Western blot analysis of global histone acetylation (acetylated histones H3 and H4) in T cells
treated as described in Figure 1A. Data are
representative of n = 2 independent experiments.
(C) Western blot analysis of H3K9-14 and H3K27
acetylation in T cells treated as described in Figure 1A. Data are representative of n = 2 independent experiments.
(D) Genome-wide chromatin immunoprecipitation
sequencing (ChIP-seq) analysis of acetylation of
H3K27 in T cells treated as described in Figure 1A.
On the y axis, every line represents the acetylation
profile of a specific gene. Genes were clustered
according to the H3K27 acetylation profile pattern.
Reported on the x axis is the distance from the
transcription start site (TSS) of every gene. The
bars on the side of each graph represent the fold
enrichment, following a color scheme (orange,
high enrichment; blue, low enrichment). n = 2
biological replicates.
(E) Global representation of the data shown in (D)
(day 9) as an enrichment profile. Culture conditions
are reported in the color legend. On the y axis, the
fold enrichment is shown. Reported on the x axis is
the distance from the TSS.

tion-associated genes belonging to immune response-related pathways whose
expression was enhanced by acetate.
Among those, we found genes encoding
for IFN-g, granzymes, tumor necrosis
factor (TNF), and the transcription factor
T-bet (Tbx21), which controls IFN-g
expression (Szabo et al., 2000; Figure 3E).
Of note, acetate increased the expression of some of these transcripts, such
as Tnf and Tbx21, only at day 9, suggesting that acetate can have additional effects on T cell effector
function after prolonged glucose restriction.
Ex Vivo Acetate Treatment Enhances IFN-g Production
in Exhausted T Cells
Our in vitro culture model allowed us to tightly control glucose
availability. However, we next aimed to obtain more direct in vivo
evidence to support our findings. To this end, we isolated tumorinfiltrating lymphocytes (TILs) from B16 melanoma tumors
21 days after subcutaneous implantation in mice (Figure 4A)
and treated them with or without supplemental acetate ex vivo.
Based on earlier work (Chang et al., 2015; Ho et al., 2015), we
reasoned that, at this later time point, TILs would have experienced prolonged glucose restriction and shown some hyporesponsive phenotypes analogous to T cells cultured in 1 mM
glucose. Indeed, as in T cells cultured under glucose restriction
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(data not shown), PD-1 was highly expressed on the isolated TILs
(Figure 4B). Moreover, treating TILs for 4 h with supplemental
acetate ex vivo significantly increased the fraction of TILs expressing IFN-g after PMA-ionomycin restimulation compared
with PBS-treated TILs (Figures 4C–4E), indicating that acetate
promotes responsiveness in T cells isolated directly from the tumor microenvironment. We also co-transferred OT-I CD8+ T cells
and EL4-OVA lymphoma tumor cells into mice and, 6 days later,
administered one intraperitoneal injection of acetate (500 mg/kg)
(Figure 4F). Upon SIINFEKL peptide restimulation, we found that
acetate administration significantly increased the frequency of
IFN-g-producing donor cells isolated from the peritoneal cavity
compared with PBS-injected controls (Figures 4G–4I).
To further corroborate our findings, we isolated lymphocytes
from the blood of patients chronically infected with hepatitis C virus (HCV). We hypothesized that, in this scenario, T cells may
experience a setting that is similar to glucose restriction, whether

Figure 3. Acetate Promotes Chromatin
Accessibility in Glucose-Restricted T Cells
(A and B) ATAC-seq analysis of genome-wide
chromatin accessibility in T cells cultured as
described in Figure 1A. (A) shows comparisons on
day 5 post-activation, whereas (B) shows comparisons on day 9 post-activation. Numbers indicate chromatin regions with significantly enhanced
(orange, top left corner value) or significantly
reduced (blue, bottom right corner value) accessibility. The term of comparison for each analysis is
the 1 mM condition, either on day 5 (A) or on day 9
(B). n = 3 biological replicates. Values on the axis
show log2 reads per million (RPM).
(C) Principal-component analysis (PCA) of RNAseq data obtained from cells cultured as in Figure 1A and restimulated with PMA-ionomycin for
4 h. n = 2–3 biological replicates.
(D) Venn diagram showing the differentially expressed genes (DEGs) on day 5, on day 9, and at
both time points in cells cultured in 1 mM glucose
versus cells exposed to acetate 1 day prior to
analysis. DEGs were filtered on adjusted p values
lower than 0.1 and fold changes greater than 30%.
n = 2–3 biological replicates.
(E) Gene ontology analysis of the DEGs identified
from comparison of cells cultured in 1 mM glucose
versus cell exposed to acetate. The color-coding
refers to (D). The heatmaps show a selection of
genes belonging to the identified gene ontology
terms. Gene ontology terms and genes of particular interest are highlighted in red. Numbers
included in the bars indicate the number of DEGs
belonging to each gene ontology term. The top 5
gene ontology terms are shown. Blue, low
expression; orange, high expression.

from a lack of available substrate or a lack
of ability to acquire substrate, during their
response to persistent virus infection that
may potentially lead to T cell exhaustion
and/or hyporesponsiveness (Bengsch
et al., 2016; Wedemeyer et al., 2002).
We found that acetate treatment
increased the expression of effector cytokines such as IFN-g
and TNF only in CD8+ T cells expressing high levels of PD-1
compared with PBS-treated counterparts (Figure 4J and 4K).
Of note, acetate also enhanced the expression of XCL-1 while
not affecting CCL-3 and interleukin-2 (IL-2) expression (Figures
S3A–S3C). Taken together, our data show that exogenous acetate increases histone acetylation, chromatin accessibility, and
cytokine production even in cells under prolonged glucose
restriction.
The Enhancing Effect of Acetate on IFN-g Production Is
Dependent on ACSS Enzymes
We reasoned that acetate was able to restore the function of
glucose-restricted T cells by providing cells with an alternative
substrate for dynamic histone acetylation required for activation-induced gene expression. This process would require the
ACSS-mediated conversion of cytosolic acetate to acetyl-CoA
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(Bulusu et al., 2017; Mews et al., 2017). We next tested whether
the acetate-dependent rescue of cytokine production was
dependent on ACSS2. We used short hairpin RNAs (shRNAs)
to selectively silence Acss2 (Acss2 shRNA; Figure 5A). Suppression of ACSS2 by Acss2 shRNA rendered glucose-restricted
T cells less responsive to the acetate-driven increases in IFN-g
production (Figure 5B), an effect that was accompanied by
reduced incorporation of 14C carbon from radioactively labeled
acetate into histones (Figure 5C). This did not reflect a histonespecific event because acetate-derived carbon incorporation
into fatty acids was also diminished in Acss2 shRNA-treated
T cells (Figure 5D), presumably reflecting diminished overall
availability of the acetyl-CoA donor. Together, these data
support the view that, in glucose-restricted T cells, cytokine
production can be promoted by exogenous acetate through
ACSS2-dependent production of acetyl-CoA, which serves as
a donor for histone acetylation, promoting activation-induced
gene expression.
To validate our approach, we traced heavy labeled 13C-acetate
into tricarboxylic acid (TCA) cycle intermediates using mass
spectrometry in T cells transduced with Acss1/2 shRNA and
observed decreased 13C incorporation into fatty acids and TCA
cycle intermediates (Figure 5E). Enforced expression of Acss2
in T cells increased 13C-acetate-derived carbon incorporation
in citrate and fatty acids (Figure 5F). Together, these data indicate
that ACSS enzymes mediate the conversion of exogenously supplied acetate to acetyl-CoA, which then feeds into different metabolic pathways.
ACSS2 Expression Contributes to Optimal Effector T
Cell Function In Vivo
To circumvent possible confounding issues of adding exogenous acetate to cultured cells, we assessed the role of ACSS2
on IFN-g production by T cells in an in vivo setting. We remained
focused on ACCS2 because this isoform was expressed by
CD8+ T cells (Figure S2A), was shown to be critical for acetate
utilization (Comerford et al., 2014), and because of our
Acss2 shRNA data (Figures 5A–5F). We subcutaneously injected
1 3 106 EL4-OVA lymphoma tumor cells and then intravenously
transferred 5 3 106 activated OVA-specific OT-I cells transduced with either control or Acss2 shRNA into Thy1.1+ recipient

mice 5 days post-tumor transplantation (Figure 5G). On day 7,
we examined donor OT-I T cells in the peripheral blood and
found that Acss2 knockdown significantly reduced the fraction
of cells capable of producing IFN-g and negatively affected the
amount of IFN-g produced by the cells (Figures 5H–5J). Consistent with these findings, tumor clearance was impaired in mice
that received Acss2 shRNA-transduced OT-I T cells compared
with those that received OT-I T cells transduced with the control
shRNA (Figure 5K). Further analysis revealed that TILs expressing Acss2 shRNA exhibited reduced IFN-g expression compared
with TILs expressing control shRNA (Figures 5G and 5L–5N).
These data suggest that antigen-specific T cell effector functions
are supported by ACSS2 under nutrient-limiting conditions such
as cancer, presumably by permitting T cells to utilize endogenous acetate.
DISCUSSION
T cells must acquire sufficient nutrients to engage the appropriate metabolism to support effector functions during infection
and cancer (Buck et al., 2015, 2017; Buck et al., 2017; Chang
et al., 2013; Michalek and Rathmell, 2010; O’Sullivan and
Pearce, 2015; Pearce et al., 2013). Nutrient competition can
remarkably influence the immune response, and nutrient depletion in the tumor microenvironment can lead to T cell hyporesponsiveness and tumor progression (Chang et al., 2015; Ho
et al., 2015; Mellor and Munn, 2008; Mockler et al., 2014). A
recent paper showed that TILs in renal cell carcinoma suffer
from glycolytic and mitochondrial insufficiency, which impairs
their function (Siska et al., 2017), further highlighting the importance of appropriate metabolic remodeling in these cells.
As a primary energy resource, glucose plays an essential role
in supporting cellular bioenergetics and maintaining normal cell
function. When transiting to environments with limited nutrients
and oxygen, cancer cells reprogram their metabolism to cope
with environmental changes in a manner dependent on alterative
substrates, as do immune cells. We found that acetate, a unique
metabolite positioned at the intersection of metabolism and
epigenetic regulation, enhances IFN-g production from T cells
during prolonged glucose restriction. The maintenance of
MCT-1, MCT-4, and ACSS2 expression over a range of glucose

Figure 4. Supplemental Acetate Increases IFN-g Production by TILs
(A) Growth curve of B16 melanoma tumors subcutaneously implanted in C57BL/6 recipient mice. Data show the average of two perpendicular diameters ± range.
14 mice were monitored.
(B) FACS analysis of PD-1 expression in splenic CD62L CD44+ CD8+ T effector cells and CD8+ tumor-infiltrating lymphocytes (TILs) isolated on day 21 posttumor implant. Data are representative of 3 independent experiments.
(C) FACS analysis of IFN-g production by TILs isolated 21 days post-tumor implantation and treated overnight with either PBS or 5 mM acetate. Numbers show
percentages of IFN-g+ cells. FACS plots are representative of 3 independent experiments.
(D and E) Quantification of percentages of IFN-g+ cells (D) and MFI of IFN-g staining (E) as in (C). Values are normalized to the PBS condition. Mean ± SEM, paired
Student’s t test; data were pooled from 3 independent experiments.
(F) 10 3 106 EL4-OVA lymphoma cells were injected intraperitoneally, and 2 3 104 naive OT-I CD8+ T cells were injected intravenously into CD45.1+ C57BL/6
recipient mice. 6 days later, mice received a single intraperitoneal bolus of 500 mg/kg acetate or PBS. Analysis was performed 1 day later.
(G) FACS analysis of IFN-g production by OT-I CD8+ T cells isolated from the peritoneal cavity of recipient mice. Numbers show percentages of IFN-g+ cells.
FACS plots are representative of 2 independent experiments.
(H and I) Quantification of percentages of IFN-g+ cells (H) and MFI of IFN-g staining (I) as in (G). Values are normalized to the PBS condition. Mean ± SEM,
Student’s t test; data were pooled from 2 independent experiments.
(J and K) FACS analysis of IFN-g (J) and TNF (K) production by PBMCs isolated from the blood of chronically infected HCV patients, treated overnight with either PBS
or 5 mM acetate. Data show MFI of IFN-g and TNF staining. Values are normalized to the PBS counterparts. Mean ± SEM, paired Student’s t test; data from 9 donors.
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concentrations indicates that T cells maintain the ability to acquire and utilize acetate in situations when glucose becomes
limited. Although acetate was able to restore cytokine production in these cells, and it contributed to histone acetylation, it
did not replace the effects of glucose in terms of lactate production and proliferation. Acetate feeds into the cellular pool of
acetyl-CoA and takes part in the TCA cycle and in subsequent
anabolic pathways, such as fatty acid, cholesterol, and hexosamine biosynthesis (Puleston et al., 2017). It is possible that acetate does not substitute for glucose in the glycolysis pathway
and in those branching from it, such as the pentose phosphate
and serine biosynthesis pathways, which are key to sustaining
T cell proliferation (Ma et al., 2017).
Our data highlight the role of acetate as an alternative carbon
source for histone acetylation in T cells when access to glucose
is limited. Although our studies did not investigate ACSS localization, it is possible that the observed enhancement in T cell cytokine production after acetate treatment is the result of differential
expression of ACSS2 in the nuclear compartment, which has
been shown to directly maintain histone acetylation in cancer
cells and neurons (Bulusu et al., 2017; Mews et al., 2017). In
our in vitro culture system, we used 5 mM sodium acetate, which
may be considered a non-physiological concentration because
acetate levels in healthy human and murine blood range from
50 to 600 mM (Hosios and Vander Heiden, 2014). However, during
infection, serum acetate concentrations in mice have been
shown to reach 2–5 mM (Balmer et al., 2016). Also, chronic alcoholics have blood acetate levels in the range of 1 mM, indicating
that blood acetate levels can be much higher depending on the
context (Nuutinen et al., 1985). It is also interesting to consider
that acetate levels in local microenvironments and particular
niches may be higher than what is measured in the blood. A
recent study has revealed that diet-derived short-chain fatty
acids (SCFAs), including acetate, boost CD8+ T cell effector function by enhancing cellular metabolism (Trompette et al., 2018).
More work will need to be done to determine the relevance of
acetate utilization by T cells in a variety of in vivo settings.

Our data showed that supplemental acetate enhances global
acetylation of histones and that 263 genes had enhanced accessibility after acetate treatment (Table S1A), and within these
peaks were genes, such as Bhlhe40, with important roles in
T cell function (Lin et al., 2014; Li et al., 2018, J. Immunol., abstract). Acetate exposure also slightly increased accessibility
to the promoter region of T-bet (encoded by the gene Tbx21),
which may correlate with the increased T-bet gene expression
evident after acetate treatment (Figure 3E). Of note, the IFN-g
gene was equally accessible in acetate-treated and -untreated
cells. This suggested to us that mechanisms in addition to chromatin accessibility, such as transcription factor binding driving
gene expression, contribute to differences in IFN-g production
upon acetate exposure. Overall, our data imply that, within the
genes represented by the open chromatin peaks, there are
genes that encode proteins that regulate the expression of the
461 DEGs emerging from the RNA-seq data of day 9 acetatetreated cells. Although not addressed in this study, the relationship between genes in open chromatin and DEGs as well as how
these DEGs regulate T cell function are subjects of future
investigation.
In summary, we have shown that prolonged glucose restriction contributes to T cell hyporesponsiveness characterized by
defects in IFN-g production and that administration of acetate
promotes chromatin accessibility, histone acetylation, and cytokine production in glucose-restricted T cells in an ACSS-dependent manner. Recent studies have shown that exhausted T cells
have progressively acquired, exhaustion-associated DNA
methylation programs (Pauken et al., 2016) and that blocking
this epigenetic reprogramming may boost immune checkpoint
blockade therapies (Ghoneim et al., 2017). The SCFA acetate
can promote chromatin accessibility, histone acetylation, and
IFN-g production in T cells rendered hyporesponsive by glucose
restriction. Understanding nutrient competition in the tumor
microenvironment and how this affects T cell nutrient acquisition
may be an important component in the generation of future therapies to promote durable T cell immunity in cancer.

Figure 5. Cell-Intrinsic ACSS2 Expression Contributes to Optimal Effector T Cell Function and Anti-tumor Immunity In Vivo
(A) Western blot analysis of ACSS2 in T cells transduced with either control (Ctrl) luciferase shRNA or Acss2 shRNA. Data are representative of 2 independent
experiments.
(B) FACS analysis of IFN-g MFI in T cells cultured in 1 mM glucose, transduced with Ctrl shRNA or Acss2 shRNA, and treated with or without acetate. Values were
normalized to the 1 mM glucose condition. Mean ± SEM, n = 2 independent experiments.
(C and D) Quantification of [1,2-14C] acetate-derived 14C incorporation in histones (C) and lipids (D) extracted from T cells cultured in 10 mM glucose medium.
Values are normalized to Ctrl shRNA. Mean ± SEM, Student’s t test; n = 3 independent experiments.
(E and F) Gas chromatography-mass spectrometry (GC-MS) analysis of 13C-acetate-derived 13C fractional contribution in metabolites extracted from T cells
transduced with Ctrl shRNA or Acss1/2 shRNA (E), Ctrl empty vector (Ctrl overexpression [OE]), or Acss2 enforced expressor (Acss2-OE) (F). Mean, Student’s
t test; n = 3 biological replicates.
(G) 1 3 106 EL4-OVA lymphoma cells were injected subcutaneously into Thy1.1+ C57BL/6 recipient mice. 5 days later, mice were intravenously administered 5 3
106 OT-I CD8+ T cells transduced with Ctrl shRNA or Acss2 shRNA. Analysis of blood CD8+ T cells was performed 2 days later.
(H) FACS analysis of IFN-g production by OT-I CD8+ T cells isolated from the blood of recipient mice. Numbers show percentages of IFN-g+ cells. FACS plots are
representative of 2 independent experiments.
(I and J) Quantification of percentage of IFN-g+ cells (I) and MFI of IFN-g staining (J) as in (H). Values are normalized to the Ctrl shRNA condition. Mean ± SEM,
Student’s t test; data were pooled from 2 independent experiments.
(K) Growth curve of EL4-OVA lymphoma tumors, subcutaneously implanted in Thy1.1+ C57BL/6 recipient mice, upon administration on day 5 post-implant of PBS
or OT-I CD8+ T cells transduced with either Ctrl shRNA or Acss2 shRNA. Data show the average of two perpendicular diameters ± SEM; two-way ANOVA with
Tukey’s multiple comparisons test; n = 4 mice/group, representative of 2 independent experiments.
(L) FACS analysis of IFN-g production by OT-I CD8+ TILs isolated from tumors of recipient mice. Numbers show percentages of IFN-g+ cells of the shRNAtransduced GFP+ population. FACS plots are representative of 3 independent experiments.
(M and N) Quantification of percentages of IFN-g+ cells (M) and MFI of IFN-g staining (N) as in (L). Mean ± SEM, Student’s t test; data from 3 experiments.
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Further information and requests for resources and reagents should be directed to and will be made available upon reasonable
request by the Lead Contact, Erika L. Pearce (pearce@ie-freiburg.mpg.de).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice and tumor models
OT-I transgenic mice (C57BL/6-Tg(TcraTcrb)1100Mjb/J; Jax, 003831), CD45.1+ C57BL/6J (B6.SJL-Ptprca Pepcb/BoyJ; Jax,
002014), Thy1.1+ C57BL/6J (B6.PL-Thy1a/CyJ; Jax, 000406) and C57BL/6J (Jax, 000664) mice were purchased from the Jackson
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Laboratory and were housed under specific pathogen-free conditions at the Max Planck Institute of Immunobiology and Epigenetics
or at Washington University School of Medicine, according to the Institutional Animal Use and Care Guidelines. Experimental procedures have been authorized by animal welfare committees at the Washington University School of Medicine or at the Max Planck
Institute of Immunobiology and Epigenetics. All procedures have been carried out following Institutional Animal Use and Care Guidelines in compliance with US, or German and European regulations.
Adult mice (older than 8 weeks old) of both sexes were used in the experiments reported in the manuscript. Comparisons were
performed between sex- and age-matched mice.
For the experiments in Figures 4A–4E, the flanks of CD45.1+ C57BL/6 mice were shaved and the mice were subcutaneously injected with 106 B16 melanoma tumor cells in 100 mL PBS. Tumor growth was monitored every 2-3 days by measuring the diameter
of the tumor mass. On day 21 after tumor implant, mice were humanely euthanized and the tumor mass harvested and further processed (see below). For the experiments in Figures 4F–4I, 107 EL4-OVA lymphoma tumor cells were intraperitoneally injected in
200 mL of PBS in CD45.1+ C57BL/6 mice. Concomitantly, 2x104 naive OT-I CD8+ T cells were intravenously injected in the same
mice. 6 days after the tumor transfer, mice were treated with either a single bolus of sodium acetate in PBS (500 mg/Kg) or with
PBS alone. 1 day later, mice were euthanized and the peritoneal content was harvested for further analysis. For experiments in
Figures 5G–5N, the flanks of Thy1.1+ C57BL/6 mice were shaved and the mice were subcutaneously injected with 106 EL4-OVA
lymphoma tumor cells in 100 mL PBS. 5 days later, mice received 5x106 activated OT-I cells transduced with the viruses indicated
in the text. On day 7, mice were bled and the cells processed for further analysis. Tumor growth was monitored every 2-3 days by
measuring the diameter of the tumor mass.
Human blood analysis
Human samples were obtained according to German federal guidelines, local ethics committee regulations (Albert-Ludwigs-University, Freiburg, Germany, HBUF 474/14 and 243/18) and the Declaration of Helsinki (1975). 8/9 blood samples were obtained from
male individuals, between 46 and 72 years old. 1/9 blood sample was obtained from a female individual, 56 years old.
Blood samples from patients chronically infected with HCV were processed to isolated PBMCs that were then stored at 80 C until
analysis. PBMCs were treated overnight with 5 mM sodium acetate or PBS, in medium containing FBS. Cells were then restimulated
with PMA/Ionomycin and brefeldin A for 4 hours before processing them for surface and intracellular staining.
Cell culture
OVA peptide-specific T cells were isolated from spleens and peripheral lymph nodes of OT-I transgenic mice (older than 8 weeks old,
sex- and age-matched) and activated with the ovalbumin peptide SIINFEKL (OVA257-264, 100 ng/ml, New England Peptide). T cells
were cultured in RPMI 1640, added with 10% heat-inactivated fetal bovine serum (GIBCO, lot n. 1640960), glutamine (4 mM), penicillin/streptomycin (1%), b-mercaptoethanol (55 mM) and glucose (concentrations indicated in the text). Cells were grown at 37 C, in
5% CO2, atmospheric O2, in a humidified incubator. Briefly, cells were activated on day 0 with OVA257-264, with rhIL-2 (100 U/ml,
Peprotech) in medium containing 25 mM glucose. After 3 days, cells were either kept in 25 mM glucose or switched to 1 mM glucose
for 1 or 5 days. 1 day before analysis, cells maintained in 1 mM glucose were treated with or without 5 mM sodium acetate (Sigma) or
valproic acid (1 mM, Sigma). Starting from day 2, and every day, cultured cells were harvested, washed, counted and plated at a
concentration of 106 cells/ml in fresh medium with rhIL-2.
B16 melanoma tumor cells (kindly provided by Dr. Marco Colonna) and EL4-OVA lymphoma tumor cells (E.G7-OVA [derivative of
EL4]; ATCC, CRL-2113) were cultured in the medium described above, with addition of 10 mM glucose, and in the culture conditions
previously described. Additional information regarding the sex of the cell lines could not be found on the ATCC website.
METHOD DETAILS
Tumor processing
Solid tumors (Figures 4A–4E and 5G–5N) were excised from mice at the indicated time post-implant and kept at +4 C. Isolated
tumors were finely chopped and treated with type IA collagenase (Sigma, 1 mg/ml) and DNase I (Sigma, 50 mg/ml) in Hanks’ Balanced
Salt Solution (HBSS, Hyclone) for 1 hour at 37 C. After digestion, cells were washed and filtered through a 70 mm strainer to obtain
single cell suspensions.
Retroviral transduction
OT-I CD8+ T cells were activated with OVA257-264 and rhIL-2 (100 U/ml) for 27 hours in the previously described medium added with
10 mM glucose. Cells were then transduced with viruses expressing short hairpin RNA (hp) against luciferase (Ctrl Hp -GFP-), Acss2
(Acss2 Hp -GFP-), Acss1 (Acss1 Hp -hCD8-) or with the expression constructs (Ctrl OE or Acss2 OE -both expressing GFP-). Transduction was performed in the previously described medium added with polybrene (Sigma, 8 mg/ml), HEPES (Hyclone, 10 mM), glutamine (4 mM) and rhIL-2 (100 U/ml). Cells were centrifuged at 2500 rpm, for 90 minutes at 30 C, followed by 3 hours resting in the same
medium. Transduced cells were then used for further analysis.
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Flow cytometry
The following antibodies were used to perform surface and intracellular staining: anti-CD8a (53-6.7, Biolegend); anti-CD44 (IM7,
Biolegend); anti-CD45.1 (A20, Biolegend); anti-CD45.2 (104, Biolegend); anti-PD-1 (J43, Invitrogen); anti-CD25 (3C7, Biolegend);
anti-CD69 (H1.2F3, Biolegend); anti-CD62L (MEL-14, Biolegend); anti-CD71 (RI7217, Biolegend); anti-Granzyme B (NGZB,
eBioscience); anti-IFNg (XMG1.2, Biolegend); anti-GFP (FM264G, Biolegend). Live cell were identified using the LIVE/DEAD fixable
dead cell stain from Invitrogen.
Surface staining was performed in PBS containing 2% FBS and EDTA (2 mM), on ice for 30 minutes. Cytokine production was
analyzed by intracellular staining upon restimulation with phorbol 12-myristate 13-acetate (PMA, Sigma, 50 ng/ml)/ionomycin
(Sigma, 500 ng/ml) in presence of brefeldin A (Biolegend, 0.1%) for 4 hours, or with SIINFEKL peptide (100 ng/ml) in presence of
brefeldin A for 12 hours. After stimulation, cells underwent surface staining, followed by fixation in Cytofix/Cytoperm fixation buffer
(BD Biosciences) at +4 C for 15 minutes. Cells were then thoroughly washed, antibodies against intracellular antigens were added in
presence of 1X permeabilization buffer (BD Biosciences) and the suspension was incubated for 45 minutes, on ice in the dark.
CellTrace Violet (CTV) reagent (Invitrogen) was used to assess cell proliferation following the manufacturer recommendations. Cell
proliferation was measured based on the fraction of live cells that diluted CTV over a period of 24 hours. Samples were assessed
with FACSCalibur, FACSCanto II or LSRFortessa analyzers (BD Biosciences), or sorted using FACSAria cell sorters. Acquisition
data were analyzed with FlowJo software (TreeStar).
Lactate measurement
Production of lactate, as a measure of aerobic glycolysis, was quantified in the supernatant of cultured cells 24 hours after seeding
106 cells/mL. Quantification was performed using a Roche Cedex Bio analyzer following manufacturer recommendations.
ELISA
Quantification of secreted IFN-g was assessed by ELISA (RND Systems) following manufacturer recommendations. Supernatant
was collected 4 hours after PMA/Ionomycin restimulation of 106 cells/mL.
Metabolomic analysis
Upon retroviral transduction, GFP+ cells were sorted by flow cytometry. Cells were then cultured in the above described medium
containing 10 mM glucose, in presence of 5 mM of uniformly-labeled 13C acetate, for 24 hours. Cells were washed with 0.9%
NaCl and kept on ice. Intracellular metabolite extraction was performed with 70% ethanol, previously warmed up to 70 C. Samples
were centrifuged, and the supernatants collected and dried under vacuum. Dried pellets were further processed and analyzed using
gas chromatography-mass spectrometry (Agilent).
Real time quantitative PCR
RNA was extracted using RNAsolv reagent (Omega) according to manufacturer instructions. RNA to cDNA conversion was performed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantification of target genes was done
by quantitative PCR using Taqman technology (Applied Biosystems). Reaction mixes were run on the QuantStudio 3 Applied
Biosystems thermal cycler. TaqMan primer pairs used to quantify target genes were as follow: Ifng Mm01168134_m1; Hprt
Mm03024075_m1 (Applied Biosystems).
Western blotting
For western blot analysis cells were washed with ice cold PBS and lysed in lysis buffer (20 mM Tris-HCl, [pH 7.5], 150 mM NaCl, 1 mM
Na2EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4, 1 mg/mL
leupeptin (Cell Signaling Technologies) supplemented with 1 mM PMSF. Samples were frozen and thawed 3 times followed by
centrifugation at 20000 g for 10 min at +4 C. Cleared protein lysate was denatured with LDS loading buffer for 10 min at 70 C,
and loaded on precast 4% to 12% bis-tris protein gels (Life Technologies). Proteins were transferred onto nitrocellulose membranes
using the iBLOT 2 system (Life Technologies) following the manufacturer’s protocols. Membranes were blocked with 5% w/v milk
and 0.1% Tween-20 in TBS and incubated with the appropriate antibodies in 5% w/v BSA in TBS with 0.1% Tween-20 overnight
at 4 C. The following antibodies were used: anti-a-tubulin (Cell Signaling); anti-ACSS2 (Thermo Scientific); anti-MCT-4 (Santa
Cruz); anti-MCT-1 (Santa Cruz); anti-H3 (Cell Signaling); anti-H4 (Cell Signaling); anti-Ac-H3 (Millipore); anti-Ac-H4 (Millipore); antiAc-H3K9/14 (Diagenode); anti-Ac-H3K27 (Diagenode). All primary antibody incubations were followed by incubation with secondary
HRP-conjugated antibodies (Pierce) in 5% milk and 0.1% Tween-20 in TBS and visualized using SuperSignal West Pico Chemiluminescent Substrate (Pierce) on Biomax MR film (Kodak). Quantification of western blots was performed by densitometry using the
ImageJ software (NIH). Arbitrary units (AU) were corrected for background signal and normalized to the loading control.
Analysis of 14C acetate incorporation into histones
Cells were treated with 1 mCi/ml sodium [1,2-14C] acetate (Perkin Elmer), overnight. After two washes in ice-cold PBS, cell pellets
were re-suspended in 500 mL NP-40 buffer (0.1% NP-40, 10 mM HEPES, 5 mM MgCl2, 0.25 M Sucrose) and incubated on ice for
10 minutes. Lysates were washed with the same buffer without NP-40 and spun down at 6000 g for 10 minutes. Histone were
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extracted in 500 mL of 0.8 M HCl, in shaking overnight and samples were then centrifuged at +4 C, 20.000 g for 30 minutes. Supernatants were neutralized with 40 mL of 10 N NaOH and radioactivity was calculated using Ultima Gold scintillation fluid.
Analysis of 14C acetate incorporation into lipids
Cells were treated with 1 mCi/ml sodium [1,2-14C] acetate (Perkin Elmer), overnight. After two washes in ice-cold PBS, cells were
lysed with 0.6 mL of MeOH solution. 0.4 mL of CHCl3 was added to lysate and vortexed for 30 s. Lysates were then centrifuged
for 5 minutes at 1000 rpm for phase separation. Soluble lipid fraction was collected as the lower layer and radioactivity was counted
using Ultima Gold scintillation fluid.
RNA sequencing analysis
RNA was extracted using the RNAsolv reagent (Omega) according to manufacturer instructions and quantified using Qubit 2.0
(Thermo Fisher Scientific) following the manufacturer’s instructions. Libraries were prepared using the TruSeq stranded mRNA kit
(Illumina) and sequenced in a HISeq 3000 (Illumina) by the Deep-sequencing Facility at the Max-Planck-Institute for Immunobiology
and Epigenetics. Sequenced libraries were processed with the Galaxy platform and deepTools (Afgan et al., 2016; Ramı́rez et al.,
2016), using STAR (Dobin et al., 2013), for trimming and mapping, and featureCounts (Liao et al., 2014) to quantify mapped reads.
Raw mapped reads were processed in R (Lucent Technologies) with DESeq2 (Love et al., 2014), to determine differentially expressed
genes and generate normalized read counts to visualize as heatmaps using Morpheus (Broad Institute). Gene ontology analysis was
performed used the free online platform DAVID (Huang et al., 2009a, 2009b). RNA sequencing data are deposited in GEO under the
following subseries code: GSE128591.
ATAC sequencing analysis
Libraries were prepared using the Nextera DNA library Prep Kit (Illumina) adapting a published protocol (Buenrostro et al., 2015).
Briefly, 5x104 T cells treated as described were washed in PBS and then lysed in 10 mM Tris-HCl, pH 7.4,10 mM NaCl, 3 mM
MgCl2 and 0.1% Igepal CA-630 (all Sigma). Nuclei were then spun down and then resuspend in 25 mL TD (2x reaction buffer),
2.5 mL TDE1 (Nextera Tn5 Transposase) and 22.5 mL nuclease-free water, incubated for 30 min at 37 C. DNA was purified with
the QIAGEN MinElute PCR Purification Kit (Thermo Fisher Scientific). PCR amplification was performed with the NEBNext HighFidelity 2x PCR Master Mix (New England Labs) using custom Nextera PCR Primers containing barcodes. Adaptors were removed
with AMPure XP beads according to manufacturer’s protocol. Libraries were quantified with the Qubit and submitted for sequencing
with a HISeq 3000 (Illumina) by the staff at the Deep-sequencing Facility at the Max-Planck-Institute for Immunobiology and Epigenetics. Sequenced samples were trimmed with Trimmomatic (Bolger et al., 2014), mapped using Bowtie2 (Langmead and Salzberg,
2012) and replicate mapped files merged with SAM tools (Li et al., 2009). Coverage files were generated with deepTools. Open
chromatin and differentially regulated chromatin was detected with MACS2 (Zhang et al., 2008) with a p value < 1x107 and a q value
of less than 0.1 and a 4 fold enrichment threshold. Bed files were analyzed with Bedtools (Quinlan and Hall, 2010). ATAC sequencing
data are deposited in GEO under the following subseries code: GSE128592.
ChIP sequencing analysis
Fixed cell pellets (1% paraformaldehyde, 10 minutes, RT) were processed for multiplex RELACS (Arrigoni et al., 2018) and sequenced
by the staff at the Deep-sequencing Facility at the Max-Planck-Institute for Immunobiology and Epigenetics. Sequenced samples
were trimmed with Trimmomatic, mapped using Bowtie2 and replicate mapped files merged with SAM tools. Heatmaps and profile
plots were generated and visualized with deepTools. ChIP sequencing data are deposited in GEO under the following subseries
code: GSE128593.
QUANTIFICATION AND STATISTICAL ANALYSIS
Comparisons between two groups were performed using unpaired or paired, two-tailed, Student’s t test. Comparisons between
more than two groups were performed using one-way or two-way ANOVA and Tukey’s multiple comparison test. Statistical analysis
was performed using Graphpad Prism 7 Software. Statistical significance: * p < 0.05; ** p < 0.005; *** p < 0.0005; **** p < 0.0001.
Further details on statistical analysis are listed in the figure legends.
DATA AND SOFTWARE AVAILABILITY
Accession numbers
RNA, ATAC and ChIP sequencing data presented in this manuscript are deposited in GEO under the superseries accession number
GSE128594.
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Figure S1. While promoting IFN-γ production, acetate does not affect expression of surface
markers, granzyme B, or cell size of glucose-restricted T cells. Related to Figure 1.
A, FACS analysis of IFN-γ production by T cells cultured continuously for 5 or 9 days in 25 mM
glucose or switched to 1 mM glucose on day 3 and cultured as described in Fig. 1A. Numbers show
percentage of IFN-γ+ cells. FACS plots are representative of n=3 independent experiments. B,
Quantification of IFN-γ production as MFI of the CD8+ population as shown in A. Values were
normalized to the 1 mM condition. Mean ± SEM; Student’s t test; n=3 independent experiments. C,
Quantification of lactate production, as measure of aerobic glycolysis, in the medium of cells cultured
for 24 hours in the indicated conditions. Mean ± SEM; n=3 independent experiments. D, FACS
analysis of surface expression of the indicated markers on T cells cultured as described in Fig. 1A.
FACS plots show representative data of n=2 independent experiments. E, FACS analysis of the
physical parameters forward scatter (FSC, indicating cell size) and side scatter (SSC, indicating the cell
shape complexity) of T cells cultured as in Fig. 1A. Analysis was performed at day 5 post-activation.
No previous gating strategy was applied before plotting FSC and SSC. The gate indicates the FSC/SSC
gate used throughout the manuscript for further analysis. F, FACS analysis of Granzyme B production
by T cells cultured as described in Fig. 1A. Numbers show percentage of Granzyme B+ cells. FACS
plots are representative of n=2 independent experiments.

Figure S2. Acetate is incorporated into lipids and histones of glucose-restricted T cells. Related to
Figure 2.
A, Western blot analysis of ACSS-2 and MCT-4 in T cells cultured in different glucose concentrations.
Data are representative of n=3 (for ACSS2) and n=1 (for MCT-4) independent experiments. B,
Western blot analysis of MCT-1 in T cells cultured in different glucose concentrations. Data are
representative of n=1 experiment. C, Quantification of [1,2-14C] acetate-derived

14

C incorporation in

lipids extracted from T cells cultured in 10 mM glucose media. Mean ± SEM; n=2 independent
experiments. D, Quantification of western blots of H3K9/14 and H3K27 acetylation in T cells treated
as described in Fig. 1A. Data are representative of n=2 (n=1 for Ac-H3K9/14) independent
experiments.

Figure S3. (IIHFWRIDcetate RQ&'7FHOOVIURP+&9LQIHFWHGSDWLHQWV Related to Figure 4.
A-C, Chemokine and cytokine expression in PBMCs isolated from the blood of patients
chronically infected with hepatitis C virus (HCV). Cells were treated overnight with either PBS or
5 mM acetate. Data show MFI of the indicated parameters. Values are normalized to the PBS
counterparts. Mean ± SEM; Paired Student’s t test; data from n=9 donors.

Table S1. Acetate enhances chromatin accessibility of genes associated with T cell signaling.
Related to Figure 3.
A, List of the 263 genes associated with the 255 open chromatin peaks resulting from acetate treatment
of day 9 glucose-restricted cells, as in Fig. 3B. B, Pathway enrichment analysis of the genes indicated
in A. Gene ontology terms are listed in order of ascending p value and the number of genes associated
to each gene ontology term is indicated.

